Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Real-Life Setting
| dc.rights.license | open | en_US |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BEZIN, Julien | |
| dc.contributor.author | KLUNGEL, O. H. | |
| dc.contributor.author | LASSALLE, R. | |
| dc.contributor.author | DUREAU-POURNIN, C. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MOORE, Nicholas | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | PARIENTE, Antoine
IDREF: 13395711X | |
| dc.date.accessioned | 2020-10-20T09:13:57Z | |
| dc.date.available | 2020-10-20T09:13:57Z | |
| dc.date.issued | 2018-06 | |
| dc.identifier.issn | 1532-6535 (Electronic) 0009-9236 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/11454 | |
| dc.description.abstractEn | Long-term effectiveness of Evidence-Based Cardiovascular Medications (EBCMs) indicated after Acute Coronary Syndrome (ACS) needs to be assessed considering the combination effects for these drugs recommended in association. Using a nationwide database, we conducted a cohort study to evaluate the effectiveness of all possible incomplete EBCMs-based combinations as compared to that associating the four recommended EBCMs over up to five years of follow-up. Among the 31,668 patients included, 22.9% had ACS recurrence or died during follow-up. The risks associated with the use of 3-EBCM based combinations were 1.46 (95% confidence interval: 1.33-1.60) for the combinations without statins, 1.30 (1.17-1.43) for the combinations without angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, 1.11 (0.98-1.25) for the combinations without antiplatelet agents, and 0.99 (0.89-1.10) for the combination without beta-blockers. These findings question the interest of maintaining long-term treatment with beta-blockers in addition to the other EBCMs for post-ACS secondary prevention. This article is protected by copyright. All rights reserved. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | PharmacoEpi-Drugs | |
| dc.subject.en | CIC1401 | |
| dc.title.en | Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Real-Life Setting | |
| dc.title.alternative | Clin Pharmacol Ther | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1002/cpt.864 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 28875506 | en_US |
| bordeaux.journal | Clinical Pharmacology and Therapeutics | en_US |
| bordeaux.page | 1038-1046 | en_US |
| bordeaux.volume | 103 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - U1219 | en_US |
| bordeaux.issue | 6 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-02972187 | |
| hal.version | 1 | |
| hal.date.transferred | 2020-10-20T09:14:04Z | |
| hal.export | true | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Pharmacology%20and%20Therapeutics&rft.date=2018-06&rft.volume=103&rft.issue=6&rft.spage=1038-1046&rft.epage=1038-1046&rft.eissn=1532-6535%20(Electronic)%200009-9236%20(Linking)&rft.issn=1532-6535%20(Electronic)%200009-9236%20(Linking)&rft.au=BEZIN,%20Julien&KLUNGEL,%20O.%20H.&LASSALLE,%20R.&DUREAU-POURNIN,%20C.&MOORE,%20Nicholas&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||